Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 382 participants.
Also called NCT02301910
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 382 participants
- Sponsor
- Registry
-
NCT02301910
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT02301910. Randomized; no masking; primary purpose treatment. Start 2014-05-16 (actual); primary completion 2016-12-01 (actual). Results posted on 2025-03-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI
- Acronym
- FRIDOM1
- Condition
- Myocardial Infarction
- Intervention (Drug)
- Recombinant staphylokinase
- Intervention (Drug)
- Tenecteplase
- Lead sponsor
- Supergene, LLC
Record details
- Record id
cardio:ct-nct02301910- Content hash
7a419d06d566b97fbfe6e6ec7c89d9bcb31b999ca7b1d34f0022f9a3b582df35